Gilead(US:GILD) Benzinga·2025-10-31 17:41Core Insights - Gilead Sciences Inc reported adjusted earnings of $2.47 per share, surpassing the consensus estimate of $2.13 [1] - The company achieved revenues of $7.77 billion, exceeding the consensus of $7.45 billion, despite a 2% decline in product sales to $7.3 billion [2] Financial Performance - HIV product sales increased by 4% to $5.3 billion, while liver disease portfolio sales rose by 12% to $819 million [3] - Biktarvy sales grew by 6% to $3.7 billion, and Descovy revenues surged by 20% to $701 million [3] Guidance and Outlook - Gilead raised its fiscal 2025 adjusted earnings guidance from $7.95-$8.25 per share to $8.05-$8.25, compared to the consensus of $8.03 [4] - The sales guidance was also increased from $28.3 billion-$28.7 billion to $28.4 billion-$28.7 billion, exceeding the consensus of $28.84 billion [4] Analyst Ratings - Needham reiterated its Buy rating for Gilead with a price forecast of $133, highlighting upcoming catalysts related to HIV treatment and cell therapy [5] - Cantor Fitzgerald maintained an Overweight rating with a price forecast of $135, while RBC Capital raised its price forecast from $100 to $105 [6] Market Performance - Gilead Sciences shares were up 0.29% at $118.78 at the time of publication [6]